Fundraising Foxvacess
4 known investors
Find your way into vacess
Sign up to see every warm intro you have to vacess
- Paths you didn't know you had: your email and LinkedIn already hold routes to the vacess team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Terrestrial develops the Tacterra microarray patch platform, a dissolvable skin-patch technology for delivering therapies including GLP-1 without injection. The platform targets patients seeking more convenient, pain-free administration of next-generation therapeutics.
Founders & leadership
Investors · 4
How we know: Mission Biocapital's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Norwich Ventures's portfolio page · Not right? Tell us
How we know: Ulu Ventures's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $3.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Science Foundation | Phase I | 2020 | $256K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Science Foundation | Phase II | 2016 | $750K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $223.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $210.1K |
| National Science Foundation | Phase I | 2015 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does vacess do?
- Terrestrial develops the Tacterra microarray patch platform, a dissolvable skin-patch technology for delivering therapies including GLP-1 without injection. The platform targets patients seeking more convenient, pain-free administration of next-generation therapeutics.
- Who founded vacess?
- vacess was founded by Livio Valenti.
- Who are vacess's investors?
- vacess's investors include Mission Biocapital, Norwich Ventures, Ulu Ventures, The Engine Ventures.